The mitral valve disease market size has grown strongly in recent years. It will grow from $3.28 billion in 2025 to $3.59 billion in 2026 at a compound annual growth rate (CAGR) of 9.7%. The growth in the historic period can be attributed to increasing prevalence of heart valve disorders, growing reliance on echocardiography diagnostics, rise in surgical mitral valve repair procedures, adoption of anticoagulation therapies, improved hospital cardiac care infrastructure.
The mitral valve disease market size is expected to see strong growth in the next few years. It will grow to $5.01 billion in 2030 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to expansion of minimally invasive mitral valve procedures, rising demand for tmvr solutions, growth in remote cardiac monitoring adoption, increasing investment in valve repair devices, development of personalized therapeutic approaches. Major trends in the forecast period include advancements in precision medicine-based mitral valve therapies, integration of ai in mitral valve diagnostics and monitoring, growth of cloud-based cardiac imaging and data platforms, adoption of iot-enabled remote cardiac monitoring devices, increased use of robotic-assisted mitral valve repair systems.
The rising prevalence of vascular heart diseases is expected to drive the growth of the mitral valve disease market in the coming years. Vascular heart diseases include a range of conditions affecting the blood vessels that supply the heart or are located within the heart itself. The increase in cases is influenced by a combination of lifestyle factors, demographic shifts, medical conditions, environmental influences, and genetic predispositions. Conditions such as ischemic heart disease and hypertension can indirectly contribute to mitral valve disease by impairing the structure and function of the heart, creating issues that affect the mitral valve. For example, in November 2024, according to the Scottish Government, a Scotland-based government agency, the prevalence of any cardiovascular disease among adults rises sharply with age, reaching 42% in individuals aged 75 and older. Consequently, the growing incidence of vascular heart diseases is propelling the mitral valve disease market.
Key companies in the mitral valve disease market are focusing on the development of stented tissue valves to meet the increasing demand for minimally invasive treatment options. Stented tissue valves are designed to deliver durable and reliable performance, providing an alternative to traditional surgical procedures. For instance, in April 2024, Medtronic, an Ireland-based healthcare company, launched the Avalus Ultra valve, an advanced surgical aortic tissue valve engineered for easier implantation and improved long-term patient management. Building on a decade of clinical experience with the original Avalus valve, the Avalus Ultra features a low valve profile for simplified implantation, a PEEK base frame to maintain consistent circularity, and an industry-leading Effective Orifice Area (EOA) that may promote enhanced blood flow. The valve also includes a radiopaque coil to ensure clear visibility during future valve-in-valve procedures.
In July 2024, Edwards Lifesciences, a US-based medical technology company, acquired Innovative Bio Medical Ltd. for an undisclosed amount. This acquisition is intended to strengthen Edwards Lifesciences’ transcatheter mitral valve replacement (TMVR) capabilities, addressing unmet needs in structural heart disease and supporting long-term growth. Innovative Bio Medical Ltd. is a UK-based medical device company specializing in the development of TMVR technologies.
Major companies operating in the mitral valve disease market are Pfizer Inc., Bayer AG, Abbott Laboratories, Novartis AG, Medtronic plc, Boston Scientific Corporation, Edwards Lifesciences, ShockWave Medical Inc., Artivion Inc., TTK Health Care Limited, Braile Biomedica, JenaValve Technology Inc., 4C Medical technologies, Labcor Laboratorios Ltda, CryoLife Inc., Valcare Medical, Affluent Medical, Colibri Heart Valve LLC, Coramaze Technologies, Corcym UK Limited, HighLife Medical, Micro International Devices Inc., Neovasc Inc., Mitralign Inc., Transcatheter Technologies GmbH.
Europe was the largest region in the mitral valve disease market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the mitral valve disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the mitral valve disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs on medical devices, imaging components, and imported surgical tools have raised production and procurement costs for mitral valve repair and replacement systems, especially in regions heavily dependent on global suppliers like North America and Europe. The most affected segments include transcatheter valve devices and robotic-assisted systems due to high reliance on precision components. Some positive effects include incentivizing local manufacturing, encouraging domestic innovation, and reducing supply-chain vulnerabilities over time.
The mitral valve disease market research report is one of a series of new reports that provides mitral valve disease market statistics, including mitral valve disease industry global market size, regional shares, competitors with a mitral valve disease market share, detailed mitral valve disease market segments, market trends and opportunities, and any further data you may need to thrive in the mitral valve disease industry. This mitral valve disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Mitral valve disease is a condition affecting the mitral valve, which regulates blood flow between the heart's left atrium and left ventricle. The disease can cause the valve to become narrowed or leaky, disrupting normal blood circulation and leading to symptoms such as shortness of breath, fatigue, and irregular heart rhythms. The main goal of managing mitral valve disease is to maintain proper blood flow through the heart and prevent complications.
The primary treatments for mitral valve disease include mitral valve repair, mitral valve replacement, cardiac resynchronization therapy, and mitral valve therapeutics. Mitral valve repair involves surgical or minimally invasive techniques to correct a damaged or leaking mitral valve, aiming to restore its normal function and prevent further complications. This treatment is applied for various conditions, including mitral valve stenosis, mitral valve prolapse, and mitral valve regurgitation, and is used by hospitals, ambulatory surgical centers, and other healthcare providers.
The mitral valve disease market includes revenues earned by entities by providing services such as diagnostic imaging, surgical, and interventional procedures, alongside consultation, rehabilitation, and telemedicine services, catering to patient care and research needs. The market value includes the value of related goods sold by the service provider or included within the service offering. The mitral valve disease market also includes sales of valve repair devices, valve replacement devices, imaging and diagnostic tools. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The mitral valve disease market size is expected to see strong growth in the next few years. It will grow to $5.01 billion in 2030 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to expansion of minimally invasive mitral valve procedures, rising demand for tmvr solutions, growth in remote cardiac monitoring adoption, increasing investment in valve repair devices, development of personalized therapeutic approaches. Major trends in the forecast period include advancements in precision medicine-based mitral valve therapies, integration of ai in mitral valve diagnostics and monitoring, growth of cloud-based cardiac imaging and data platforms, adoption of iot-enabled remote cardiac monitoring devices, increased use of robotic-assisted mitral valve repair systems.
The rising prevalence of vascular heart diseases is expected to drive the growth of the mitral valve disease market in the coming years. Vascular heart diseases include a range of conditions affecting the blood vessels that supply the heart or are located within the heart itself. The increase in cases is influenced by a combination of lifestyle factors, demographic shifts, medical conditions, environmental influences, and genetic predispositions. Conditions such as ischemic heart disease and hypertension can indirectly contribute to mitral valve disease by impairing the structure and function of the heart, creating issues that affect the mitral valve. For example, in November 2024, according to the Scottish Government, a Scotland-based government agency, the prevalence of any cardiovascular disease among adults rises sharply with age, reaching 42% in individuals aged 75 and older. Consequently, the growing incidence of vascular heart diseases is propelling the mitral valve disease market.
Key companies in the mitral valve disease market are focusing on the development of stented tissue valves to meet the increasing demand for minimally invasive treatment options. Stented tissue valves are designed to deliver durable and reliable performance, providing an alternative to traditional surgical procedures. For instance, in April 2024, Medtronic, an Ireland-based healthcare company, launched the Avalus Ultra valve, an advanced surgical aortic tissue valve engineered for easier implantation and improved long-term patient management. Building on a decade of clinical experience with the original Avalus valve, the Avalus Ultra features a low valve profile for simplified implantation, a PEEK base frame to maintain consistent circularity, and an industry-leading Effective Orifice Area (EOA) that may promote enhanced blood flow. The valve also includes a radiopaque coil to ensure clear visibility during future valve-in-valve procedures.
In July 2024, Edwards Lifesciences, a US-based medical technology company, acquired Innovative Bio Medical Ltd. for an undisclosed amount. This acquisition is intended to strengthen Edwards Lifesciences’ transcatheter mitral valve replacement (TMVR) capabilities, addressing unmet needs in structural heart disease and supporting long-term growth. Innovative Bio Medical Ltd. is a UK-based medical device company specializing in the development of TMVR technologies.
Major companies operating in the mitral valve disease market are Pfizer Inc., Bayer AG, Abbott Laboratories, Novartis AG, Medtronic plc, Boston Scientific Corporation, Edwards Lifesciences, ShockWave Medical Inc., Artivion Inc., TTK Health Care Limited, Braile Biomedica, JenaValve Technology Inc., 4C Medical technologies, Labcor Laboratorios Ltda, CryoLife Inc., Valcare Medical, Affluent Medical, Colibri Heart Valve LLC, Coramaze Technologies, Corcym UK Limited, HighLife Medical, Micro International Devices Inc., Neovasc Inc., Mitralign Inc., Transcatheter Technologies GmbH.
Europe was the largest region in the mitral valve disease market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the mitral valve disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the mitral valve disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs on medical devices, imaging components, and imported surgical tools have raised production and procurement costs for mitral valve repair and replacement systems, especially in regions heavily dependent on global suppliers like North America and Europe. The most affected segments include transcatheter valve devices and robotic-assisted systems due to high reliance on precision components. Some positive effects include incentivizing local manufacturing, encouraging domestic innovation, and reducing supply-chain vulnerabilities over time.
The mitral valve disease market research report is one of a series of new reports that provides mitral valve disease market statistics, including mitral valve disease industry global market size, regional shares, competitors with a mitral valve disease market share, detailed mitral valve disease market segments, market trends and opportunities, and any further data you may need to thrive in the mitral valve disease industry. This mitral valve disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Mitral valve disease is a condition affecting the mitral valve, which regulates blood flow between the heart's left atrium and left ventricle. The disease can cause the valve to become narrowed or leaky, disrupting normal blood circulation and leading to symptoms such as shortness of breath, fatigue, and irregular heart rhythms. The main goal of managing mitral valve disease is to maintain proper blood flow through the heart and prevent complications.
The primary treatments for mitral valve disease include mitral valve repair, mitral valve replacement, cardiac resynchronization therapy, and mitral valve therapeutics. Mitral valve repair involves surgical or minimally invasive techniques to correct a damaged or leaking mitral valve, aiming to restore its normal function and prevent further complications. This treatment is applied for various conditions, including mitral valve stenosis, mitral valve prolapse, and mitral valve regurgitation, and is used by hospitals, ambulatory surgical centers, and other healthcare providers.
The mitral valve disease market includes revenues earned by entities by providing services such as diagnostic imaging, surgical, and interventional procedures, alongside consultation, rehabilitation, and telemedicine services, catering to patient care and research needs. The market value includes the value of related goods sold by the service provider or included within the service offering. The mitral valve disease market also includes sales of valve repair devices, valve replacement devices, imaging and diagnostic tools. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Mitral Valve Disease Market Characteristics
3. Mitral Valve Disease Market Supply Chain Analysis
4. Global Mitral Valve Disease Market Trends and Strategies
5. Mitral Valve Disease Market Analysis of End Use Industries
7. Global Mitral Valve Disease Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Mitral Valve Disease Total Addressable Market (TAM) Analysis for the Market
9. Mitral Valve Disease Market Segmentation
10. Mitral Valve Disease Market Regional and Country Analysis
11. Asia-Pacific Mitral Valve Disease Market
12. China Mitral Valve Disease Market
13. India Mitral Valve Disease Market
14. Japan Mitral Valve Disease Market
15. Australia Mitral Valve Disease Market
16. Indonesia Mitral Valve Disease Market
17. South Korea Mitral Valve Disease Market
18. Taiwan Mitral Valve Disease Market
19. South East Asia Mitral Valve Disease Market
20. Western Europe Mitral Valve Disease Market
21. UK Mitral Valve Disease Market
22. Germany Mitral Valve Disease Market
23. France Mitral Valve Disease Market
24. Italy Mitral Valve Disease Market
25. Spain Mitral Valve Disease Market
26. Eastern Europe Mitral Valve Disease Market
27. Russia Mitral Valve Disease Market
28. North America Mitral Valve Disease Market
29. USA Mitral Valve Disease Market
30. Canada Mitral Valve Disease Market
31. South America Mitral Valve Disease Market
32. Brazil Mitral Valve Disease Market
33. Middle East Mitral Valve Disease Market
34. Africa Mitral Valve Disease Market
36. Mitral Valve Disease Market Competitive Landscape and Company Profiles
37. Mitral Valve Disease Market Other Major and Innovative Companies
40. Mitral Valve Disease Market High Potential Countries, Segments and Strategies
41. Appendix
Executive Summary
Mitral Valve Disease Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses mitral valve disease market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for mitral valve disease? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The mitral valve disease market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Treatment Type: Mitral Valve Repair; Mitral Valve Replacement; Mitral Valve Therapeutics2) By Indication: Mitral Valve Stenosis; Mitral Valve Prolapse; Mitral Valve Regurgitation
3) By End-User: Hospitals; Ambulatory Surgical Centers; Other End-Users
Subsegments:
1) By Mitral Valve Repair: Surgical Repair; Minimally Invasive Repair; Percutaneous Mitral Valve Repair2) By Mitral Valve Replacement: Mechanical Valve Replacement; Biological Valve Replacement; Transcatheter Mitral Valve Replacement (TMVR)
3) By Mitral Valve Therapeutics: Pharmacological Treatments; Anticoagulation Therapy; Mitral Valve Repair Devices
Companies Mentioned: Pfizer Inc.; Bayer AG; Abbott Laboratories; Novartis AG; Medtronic plc; Boston Scientific Corporation; Edwards Lifesciences; ShockWave Medical Inc.; Artivion Inc.; TTK Health Care Limited; Braile Biomedica; JenaValve Technology Inc.; 4C Medical technologies; Labcor Laboratorios Ltda; CryoLife Inc.; Valcare Medical; Affluent Medical; Colibri Heart Valve LLC; Coramaze Technologies; Corcym UK Limited; HighLife Medical; Micro International Devices Inc.; Neovasc Inc.; Mitralign Inc.; Transcatheter Technologies GmbH
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Mitral Valve Disease market report include:- Pfizer Inc.
- Bayer AG
- Abbott Laboratories
- Novartis AG
- Medtronic plc
- Boston Scientific Corporation
- Edwards Lifesciences
- ShockWave Medical Inc.
- Artivion Inc.
- TTK Health Care Limited
- Braile Biomedica
- JenaValve Technology Inc.
- 4C Medical technologies
- Labcor Laboratorios Ltda
- CryoLife Inc.
- Valcare Medical
- Affluent Medical
- Colibri Heart Valve LLC
- Coramaze Technologies
- Corcym UK Limited
- HighLife Medical
- Micro International Devices Inc.
- Neovasc Inc.
- Mitralign Inc.
- Transcatheter Technologies GmbH
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 3.59 Billion |
| Forecasted Market Value ( USD | $ 5.01 Billion |
| Compound Annual Growth Rate | 8.6% |
| Regions Covered | Global |
| No. of Companies Mentioned | 26 |
